XML 20 R9.htm IDEA: XBRL DOCUMENT v3.26.3
Organization
9 Months Ended
Sep. 30, 2026
Accounting Policies [Abstract]  
Organization
1.
Organization

Overview

Alaunos Therapeutics, Inc., which is referred to herein as “Alaunos,” or the “Company,” is a biopharmaceutical company developing a pipeline of potentially transformative therapies for pulmonary arterial hypertension and related cardiopulmonary disease. The Company was historically involved in the development of adoptive TCR therapies, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs.

The Company’s operations to date have consisted primarily of conducting research and development and raising capital to fund those efforts.

As of September 30, 2026, there were 3,324,697 shares of common stock outstanding, 500 Series A-1 shares of preferred stock outstanding, 850 Series A-2 shares of preferred stock outstanding and an additional 325,852 shares of common stock reserved for issuance pursuant to outstanding stock options and warrants. The Company also has 484,156 shares available for issuance under its 2020 Equity Incentive Plan.

The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business.

Recent Developments

On October 13, 2026, the Company acquired Velaris Therapeutics, Inc., a Delaware corporation (“Pre-Acquisition Velaris”), in accordance with the terms of the Agreement and Plan of Merger, dated October 13, 2026 (the “Acquisition Agreement”), by and among the Company, Valkyrie Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“First Merger Sub”), Valkyrie Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Second Merger Sub”), and Pre-Acquisition Velaris. Pursuant to the Acquisition Agreement, First Merger Sub merged with and into Pre-Acquisition Velaris, pursuant to which Pre-Acquisition Velariswas the surviving corporation and became a wholly owned subsidiary of the Company (the “First Merger”). Immediately following the First Merger, Pre-Acquisition Velaris merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving entity (together with the First Merger, the “Asset Acquisition”). The Asset Acquisition is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.

Under the terms of the Acquisition Agreement, following the closing of the Asset Acquisition (the “Closing”), the Company issued to the stockholders of Pre-Acquisition Velaris (i) 105,286 shares of Series B Non-Voting Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”) and (ii) 33,054 shares of Series C Non-Voting Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferred Stock”), each share of which is, in each case, convertible into 1,000 shares of common stock of the Company, subject to certain conditions. In addition, shares of Series C Preferred Stock issued in respect of outstanding unvested restricted shares of Velaris common stock remain subject to the same vesting terms, and each outstanding option to purchase shares of Velaris common stock was assumed by the Company and converted into an option to purchase shares of common stock, with the number of shares and exercise price adjusted based on the exchange ratio in the Merger Agreement.

In connection with the Asset Acquisition, the Company also entered into a significant private investment in public equity (“PIPE”) transaction. The Company agreed to sell (i) 687,789 shares of common stock at a price of $1.4357 per share and (ii) 243,063 shares of Series C Preferred Stock at a price of $1,435.70 per share in the PIPE for approximately $350 million in gross proceeds. The PIPE closed on October 14, 2026. The Series C Preferred Stock are convertible into Common Stock at a ratio of 1,000 shares of common stock per share of Series C Preferred Stock, subject beneficial‑ownership limitations.

Liquidity and Going Concern

The Company has operated at a loss since its inception in 2003 and has no recurring revenue from operations. The Company anticipates that losses will continue for the foreseeable future. As of September 30, 2026, the Company had approximately $0.62 million of cash and cash equivalents. The Company’s accumulated deficit at September 30, 2026 was approximately $927.4 million. These conditions initially raised substantial doubt about the Company’s ability to continue as a going concern.

 

Subsequent to September 30, 2026, on October 14, 2026, the Company completed a private placement of 687,789 shares of common stock and 243,063 shares of Series C Non-Voting Convertible Preferred Stock, resulting in gross cash proceeds of approximately $350.0 million before deducting placement agent fees and other offering expenses. See Note 9. Subsequent Events for additional information regarding the financing.

 

 

Management evaluated the Company’s ability to continue as a going concern based on information available through the date these financial statements were issued, including the completed financing and the Company’s updated cash flow forecast. Based on this evaluation, management concluded that the Company’s existing cash resources, including the net proceeds from the financing, are sufficient to fund its planned operations and meet its obligations as they become due for at least one year from the issuance date of these financial statements.

 

The Company’s cash flow forecast is based on assumptions regarding future expenditures and operating requirements, and actual results could differ materially. The Company may require additional financing to support activities beyond the forecast period or changes to its operating plans.

Basis of Presentation

The accompanying unaudited interim condensed financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair presentation of the financial position of the Company and its results of operations and cash flows for the periods presented. The unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2025, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on March 31, 2026 and as amended by Amendment No. 1 filed with the SEC on April 30, 2026 (collectively, the “2025 Annual Report”),

The results disclosed in the condensed statements of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for the full fiscal year 2026.

Use of Estimates

The preparation of condensed financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.

 

Nasdaq Stockholders' Equity Deficiency Notice

 

On April 9, 2026, the Company received a notice (the “Notice”) from the Listing Qualifications staff of Nasdaq notifying the Company that the Company’s stockholders equity, as reported in its 2025 Annual Report, did not satisfy the continued listing requirements under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholder equity be at least $2.5 million. In its 2025 Annual Report Form 10-K, the Company reported stockholders’ equity of $2.2 million, and, as a result, did not satisfy Nasdaq Listing Rule 5550(b)(1) at that time.

 

Subsequent to September 30, 2026, the Company completed the PIPE on October 14, 2026, generating approximately $350.0 million in gross proceeds before placement agent fees and other offering expenses. In connection with the PIPE, Fairmount Healthcare Fund II, L.P. provided a limited waiver of cash-settlement rights covering 6,268 shares of Series C Preferred Stock, representing approximately $9.0 million. Before the PIPE, on October 5, 2026, the Company had received a written notice from the Listing Qualifications staff of Nasdaq informing the Company that its securities were subject to delisting due to its continued non-compliance with Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”) unless the Company timely requested a hearing before the Nasdaq Hearings Panel. The Company had timely submitted a plan to regain compliance and then timely requested a hearing, which was scheduled for November 10, 2026. On October 21, 2026, the Company disclosed its determination that the financing, including the effect of the waiver, had restored compliance with the Stockholders’ Equity Requirement.

 

On October 22, 2026, the Company received a letter from Nasdaq’s Office of General Counsel confirming that Nasdaq staff had determined that the Company had regained compliance with the Stockholders’ Equity Requirement. Nasdaq closed the matter and cancelled the November 10, 2026 hearing. The Company’s common stock continues to be listed and traded on the Nasdaq Capital Market.

 

Nasdaq will continue to monitor the Company’s compliance. If the Company does not evidence compliance when it files its Annual Report on Form 10-K for the year ending December 31, 2026, it may be subject to delisting. The September 30, 2026 balance sheet precedes the Asset Acquisition and the PIPE and therefore does not reflect their effects on stockholders’ equity. See Note 9. Subsequent

Events and Part II, Item 1A, “Risk Factors,” for additional information.

 

Nasdaq Minimum Market Value Requirement

 

On July 22, 2026, the SEC’s Division of Trading and Markets, acting pursuant to delegated authority, approved a Nasdaq rule change that would require companies listed on the Nasdaq Capital Market to maintain a market value of listed securities (“MVLS”) of at least $5.0 million. Under the approved rule, a company whose MVLS remains below $5.0 million for 30 consecutive business days would be subject to an immediate staff delisting determination without an automatic compliance period. On July 29, 2026, following the filing of notices of intention to petition for review, the SEC automatically stayed the approval order pending further Commission action. As of the date these condensed financial statements were issued, the stay remained in effect. The Company cannot predict the timing or outcome of the SEC’s review, whether or when the rule will become operative, or the implementation and measurement procedures that may apply if the stay is lifted.